Prolonged Posttreatment Virologic Control and Complete Seroreversion After Advanced Human Immunodeficiency Virus-1 Infection.
HIV-1 seroreversion
HIV-specific T cells
functional cure
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
07
10
2020
accepted:
09
12
2020
entrez:
29
1
2021
pubmed:
30
1
2021
medline:
30
1
2021
Statut:
epublish
Résumé
Possible human immunodeficiency virus (HIV)-1 clearance has rarely been reported. In this study, we describe a unique case of an HIV-positive, combination antiretroviral therapy (cART)-experienced woman with prior acquired immunodeficiency syndrome (AIDS) who has not experienced viral rebound for over 12 years since discontinuing cART. Leukapheresis, colonoscopy, and lymph node excision were performed for detailed examination of virologic (including HIV reservoir) and immunologic features. Comparisons were made with chronically infected patients and healthy controls. No HIV-specific antibodies were detected in serum. Plasma HIV ribonucleic acid (RNA) levels were <0.2 copies/mL, and, except for low-frequency HIV deoxyribonucleic acid (DNA) This represents the first report of complete seroreversion, prolonged posttreatment virus suppression, a profoundly small HIV reservoir, and persistent HIV-specific T cells in an adult with prior AIDS.
Sections du résumé
BACKGROUND
BACKGROUND
Possible human immunodeficiency virus (HIV)-1 clearance has rarely been reported. In this study, we describe a unique case of an HIV-positive, combination antiretroviral therapy (cART)-experienced woman with prior acquired immunodeficiency syndrome (AIDS) who has not experienced viral rebound for over 12 years since discontinuing cART.
METHODS
METHODS
Leukapheresis, colonoscopy, and lymph node excision were performed for detailed examination of virologic (including HIV reservoir) and immunologic features. Comparisons were made with chronically infected patients and healthy controls.
RESULTS
RESULTS
No HIV-specific antibodies were detected in serum. Plasma HIV ribonucleic acid (RNA) levels were <0.2 copies/mL, and, except for low-frequency HIV deoxyribonucleic acid (DNA)
CONCLUSIONS
CONCLUSIONS
This represents the first report of complete seroreversion, prolonged posttreatment virus suppression, a profoundly small HIV reservoir, and persistent HIV-specific T cells in an adult with prior AIDS.
Identifiants
pubmed: 33511235
doi: 10.1093/ofid/ofaa613
pii: ofaa613
pmc: PMC7824876
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa613Informations de copyright
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2020.
Références
Blood. 2012 May 17;119(20):4645-55
pubmed: 22490332
Immunity. 2008 Dec 19;29(6):1009-21
pubmed: 19062316
Arch Intern Med. 2012 Sep 10;172(16):1252-5
pubmed: 22826124
J Infect Dis. 2018 Nov 5;218(12):1954-1963
pubmed: 30085241
PLoS Pathog. 2013;9(5):e1003347
pubmed: 23671416
JAMA. 1998 Sep 23-30;280(12):1080-5
pubmed: 9757856
J Clin Microbiol. 2003 Oct;41(10):4531-6
pubmed: 14532178
Nat Immunol. 2015 Jun;16(6):563-70
pubmed: 25988888
AIDS. 2004 Jul 23;18(11):1607-8
pubmed: 15238784
Blood. 2006 Jun 15;107(12):4781-9
pubmed: 16467198
Nature. 2020 Sep;585(7824):261-267
pubmed: 32848246
Biochem Biophys Res Commun. 2007 Jan 26;352(4):889-95
pubmed: 17157815
J Virol. 2009 Jan;83(1):188-99
pubmed: 18922865
AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8
pubmed: 8959245
J Virol. 2001 Jul;75(14):6508-16
pubmed: 11413318
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8783-8
pubmed: 27432972
N Engl J Med. 2009 Feb 12;360(7):692-8
pubmed: 19213682
J Clin Microbiol. 2019 Sep 24;57(10):
pubmed: 31217270
Clin Infect Dis. 2005 Mar 15;40(6):868-73
pubmed: 15736021
J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):328-337
pubmed: 28350553
Pathog Immun. 2016 Spring;1(1):68-106
pubmed: 27430032
Sci Transl Med. 2017 Dec 6;9(419):
pubmed: 29212716
J Virol. 2009 Nov;83(22):11876-89
pubmed: 19726501
Clin Infect Dis. 2006 Mar 1;42(5):700-8
pubmed: 16447118
J Infect Dis. 2009 Sep 15;200(6):984-90
pubmed: 19656066
Lancet HIV. 2020 May;7(5):e340-e347
pubmed: 32169158
J Virol. 2009 Jan;83(1):329-35
pubmed: 18945778
AIDS. 2016 Jan 28;30(3):343-53
pubmed: 26588174
AIDS. 2006 Jun 26;20(10):1460-2
pubmed: 16791025
AIDS. 2010 Jun 19;24(10):1598-601
pubmed: 20549847
Mucosal Immunol. 2010 Mar;3(2):172-81
pubmed: 19956090
J Virol Methods. 2003 Jun 9;110(1):73-9
pubmed: 12757923
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
pubmed: 10611346
J Virus Erad. 2019 Apr 1;5(2):73-83
pubmed: 31191910
Nat Immunol. 2002 Nov;3(11):1061-8
pubmed: 12368910
PLoS Pathog. 2013 Mar;9(3):e1003211
pubmed: 23516360
J Infect Dis. 2014 May 15;209(10):1613-7
pubmed: 24286982
Nat Rev Immunol. 2014 Jul;14(7):495-504
pubmed: 24948364
AIDS. 2010 Nov 27;24(18):2803-8
pubmed: 20962613
AIDS Res Hum Retroviruses. 2006 Jul;22(7):640-7
pubmed: 16831088
PLoS Pathog. 2010 May 27;6(5):e1000917
pubmed: 20523897
J Immunol. 2009 Jun 15;182(12):7828-37
pubmed: 19494307
J Clin Microbiol. 1994 Mar;32(3):732-9
pubmed: 8195386
J Exp Med. 2006 Jan 23;203(1):35-40
pubmed: 16418398
PLoS One. 2012;7(5):e37792
pubmed: 22666392
PLoS Pathog. 2018 Jan 11;14(1):e1006792
pubmed: 29324842
Proc Natl Acad Sci U S A. 2007 Apr 17;104(16):6776-81
pubmed: 17428922
Nature. 2019 Apr;568(7751):244-248
pubmed: 30836379